• Explore /
  • Poster
  • / Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).

Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).

Abstract Poster

Authors

null

Stefania Oliva

GIMEMA, European Myeloma Network, Italy

Stefania Oliva , Elisa Genuardi , Angelo Belotti , Pio Manlio Mirko Frascione , Monica Galli , Andrea Capra , Massimo Offidani , Federico Vozella , Renato Zambello , Daniel Auclair , Ilan Kirsch , Marina Ruggeri , Allison Jacob , Antonio Ledda , Paolo Corradini , Milena Gilestro , Elena Zamagni , Pellegrino Musto , Mario Boccadoro , Francesca Gay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02203643

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8533)

DOI

10.1200/JCO.2020.38.15_suppl.8533

Abstract #

8533

Poster Bd #

433

Abstract Disclosures

Similar Posters

First Author: Enrique M. Ocio

First Author: Maria Victoria Mateos Manteca

First Author: Dan T. Vogl

First Author: Cristina Gasparetto